Literature DB >> 9061508

17-Hydroxyprogesterone response to ACTH in bilateral and monolateral adrenal incidentalomas.

G P Bernini1, G Brogi, M S Vivaldi, G F Argenio, M Sgrò, A Moretti, A Salvetti.   

Abstract

The aim of our study was to assess the frequency of 21-hydroxylase deficiency, a cause of congenital adrenal hyperplasia (CAH), in incidentally discovered asymptomatic adrenal masses (incidentalomas) and to compare the prevalence of this enzymatic disorder in monolateral (M) and bilateral (B) forms. Twenty-seven patients with incidentalomas (12 M and 15 B) and 16 sex and age-matched controls (C) received synthetic adrenocorticotropin (ACTH, 250 micrograms i.v.). Plasma 17-OHprogesterone (17-OHP) and cortisol were collected in basal conditions and after 30, 60, 90 minutes. Basal plasma 17-OHP in C [1.25 +/- 0.15 (0.61) ng/ml, mean +/- SE (SD)] was not significantly different from that in patients with M [0.85 +/- 0.13 (0.44) ng/ml] or B [0.94 +/- 0.23 (0.90) ng/ml] incidentalomas. After ACTH, 17-OHP levels significantly (p < 0.05) increased in C, in M and B incidentalomas. However, the rise in plasma 17-OHP in C both in terms of peak [2.5 +/- 0.28 (1.1) ng/ml] and of AUC values [174 +/- 16 (64) ng/ml/min] was significantly lower than that observed in M [peak 6.32 +/- 1.66 (5.7) ng/ml, p < 0.01; AUC 410 +/- 111 (385.5) ng/ml/min, p < 0.01] and in B [peak 8.84 +/- 1.98 (7.65) ng/ml, p < 0.001; AUC 613 +/- 149 (579.3), ng/ml/min, p < 0.001] incidentalomas. Individual data indicated that while 17-OHP response to ACTH in C never reached 5 ng/ml (cut-off for normal response), 16 out of 27 patients with incidentalomas (59.2%) exceeded this value. Moreover, the abnormal response was more frequently observed in B (66.6%) than in M (50%) incidentalomas. Basal and stimulated plasma cortisol did not differ among the three groups. In conclusion, our data indicate that in adrenal incidentalomas the endocrine pattern of 21-hydroxylase deficiency is very common and that this enzymatic defect is more frequent in bilateral than in monolateral lesions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9061508     DOI: 10.1007/bf03347878

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  20 in total

1.  Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome.

Authors:  M Reincke; J Nieke; G P Krestin; W Saeger; B Allolio; W Winkelmann
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

2.  Adrenocortical nodular hyperplasia: the ageing adrenal.

Authors:  J W Dobbie
Journal:  J Pathol       Date:  1969-09       Impact factor: 7.996

3.  An attenuated form of congenital virilizing adrenal hyperplasia.

Authors:  Z Rosenwaks; P A Lee; G S Jones; C J Migeon; A C Wentz
Journal:  J Clin Endocrinol Metab       Date:  1979-09       Impact factor: 5.958

4.  Comparison of two tests for heterozygosity in congenital adrenal hyperplasia (CAH).

Authors:  J Weil; F Bidlingmaier; W G Sippell; O Butenandt; D Knorr
Journal:  Acta Endocrinol (Copenh)       Date:  1979-05

5.  Adrenocortical tumor in a patient with untreated congenital adrenocortical hyperplasia owing to 21-hydroxylase deficiency: characterization of steroidogenic lesions.

Authors:  K Takayama; M Ohashi; M Haji; T Matsumoto; Y Mihara; J Kumazawa; K Kato
Journal:  J Urol       Date:  1988-10       Impact factor: 7.450

6.  Expression of steroidogenic enzyme messenger ribonucleic acids and corticosteroid production in aldosterone-producing and "nonfunctioning" adrenal adenomas.

Authors:  K Rácz; F Pinet; T Marton; B Szende; E Gláz; P Corvol
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

7.  Comparison of basal and adrenocorticotropin-stimulated plasma 21-deoxycortisol and 17-hydroxyprogesterone values as biological markers of late-onset adrenal hyperplasia.

Authors:  J Fiet; B Gueux; M Gourmelen; F Kuttenn; P Vexiau; P Couillin; M T Pham-Huu-Trung; J M Villette; M C Raux-Demay; H Galons
Journal:  J Clin Endocrinol Metab       Date:  1988-04       Impact factor: 5.958

8.  Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia.

Authors:  S Jaresch; E Kornely; H K Kley; R Schlaghecke
Journal:  J Clin Endocrinol Metab       Date:  1992-03       Impact factor: 5.958

9.  Conservative and surgical management of incidentally discovered adrenal tumors (incidentalomas).

Authors:  F Jockenhövel; W Kuck; B Hauffa; W Reinhardt; G Benker; S Lederbogen; T Olbricht; D Reinwein
Journal:  J Endocrinol Invest       Date:  1992-05       Impact factor: 4.256

10.  Screening for late-onset congenital adrenal hyperplasia in hirsutism or amenorrhea.

Authors:  H J Baskin
Journal:  Arch Intern Med       Date:  1987-05
View more
  5 in total

1.  Comparative analysis of plasma 17-hydroxyprogesterone and cortisol responses to ACTH in patients with various adrenal tumors before and after unilateral adrenalectomy.

Authors:  M Tóth; K Rácz; V Adleff; I Varga; L Fütö; C Jakab; K Karlinger; R Kiss; E Gláz
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

2.  Utility of plasma dehydroepiandrosterone sulphate determination in adrenal incidentalomas.

Authors:  G P Bernini; G F Argenio; M S Vivaldi; A Moretti; P Miccoli; P Iacconi; A Magagna; A Salvetti
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

Review 3.  The role of 21-hydroxylase in the pathogenesis of adrenal masses: review of the literature and focus on our own experience.

Authors:  L Barzon; P Maffei; N Sonino; C Pilon; L Baldazzi; A Balsamo; O Del Maschio; G Masi; M Trevisan; M Pacenti; F Fallo
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

4.  A case of congenital adrenal hyperplasia mimicking Cushing's syndrome.

Authors:  Hye Jeong Kim; Mira Kang; Jae Hyeon Kim; Sun Wook Kim; Jae Hoon Chung; Yong-Ki Min; Moon-Kyu Lee; Kwang-Won Kim; Myung-Shik Lee
Journal:  J Korean Med Sci       Date:  2012-10-30       Impact factor: 2.153

5.  Decreased steroidogenic enzyme activity in benign adrenocortical tumors is more pronounced in bilateral lesions as determined by steroid profiling in LC-MS/MS during ACTH stimulation test.

Authors:  Fidéline Bonnet-Serrano; Maxime Barat; Anna Vaczlavik; Anne Jouinot; Lucas Bouys; Christelle Laguillier-Morizot; Corinne Zientek; Catherine Simonneau; Etienne Larger; Laurence Guignat; Lionel Groussin; Guillaume Assié; Jean Guibourdenche; Ioannis Nicolis; Marie-Claude Menet; Jérôme Bertherat
Journal:  Endocr Connect       Date:  2022-07-19       Impact factor: 3.221

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.